CD274 and melanoma: In NCT03637803, MRx0518 is currently being trialled in combination with pembrolizumab in advanced solid cancers including melanoma, in patients who have progressed on anti-PD-1/PD-L1 ICI, with investigation of tolerability and initial signs of clinical benefit.